全球生物防御市场：依疾病类型、治疗方法和地区的预测（~2030年）

生物防御市场规模预计在预测期内年复合成长率为 7.01%。

为了应对潜在的生物恐怖攻击，各国政府正投入大量资源进行疫苗研发。政府为应对各种形式的生物恐怖主义所做的努力为生物防御市场上的製药公司提供了重大的扩张机会。此外，世界各国政府实施提高生物防御能力的措施。由于研发、准备规划、基础设施开发以及疫苗和药品采购资金的增加，生物防御市场成长。

依地域的展望

2023年，北美生物防御市场的市占率最大。这是因为爱滋病毒、病毒性肝炎和流感等传染病在该地区盛行。美国疾病管制与预防中心（CDC）估计，2021年美国约有 900万人被诊断出感染流感病毒。随着抗菌素抗药性的持续增加，这一趋势预计将持续下去。对抗这些传染病的廉价诊断测试、疫苗和治疗方法的需求不断成长预计将推动市场的发展。

由于慢性病的增加和生物防御措施研发活动的增加，欧洲的生物防御市场占据第二大占有率。

预计2023年至2032年亚太地区生物防御市场将大幅成长。推动市场成长的主要因素是该地区患者数量的增加。由于流感和 COVID-19 等传染病的增加，该地区的消费者面临重大的健康风险。

本报告调查了全球生物防御市场，提供了市场的定义和概述，市场成长的各种影响因素分析，市场规模推移和预测，各种区分、地区的细分，竞争环境，主要企业概况等彙整资料。

目次

第1章 执行摘要

第2章 市场概要

第3章 研究方法

第4章 市场力学

• 促进要因
  • 加强政府力道与资金投入
  • 疫苗需求不断增加
• 抑制要因
  • 发展中国家的市场渗透率较低
• 机会
  • 技术进步

第5章 市场要因分析

• 价值链分析
• 波特五力分析
• COVID-19 对全球生物防御市场的影响
• 生物防御机构预算与补助计画：依地区划分

第6章 全球生物防御市场：依疾病类型

• 概要
• 炭疽菌
• 天花
• 肉毒桿菌
• 流感
• 放射线/核
• 其他

第7章 全球生物防御市场：依治疗方式

• 概要
• 疫苗接种
• 药品

第8章 全球生物防御市场：依地区

• 世界
• 北美
• 欧洲
• 亚太地区
• 其他领域

第9章 竞合情势

• 概要
• 竞争基准测试
• 主要成长策略
• 开发专案数量最多的公司
• 主要发展分析
• 主要发展与成长策略
• 主要公司的财务趋势

第10章 公司简介

• EMERGENT
• BAVARIAN NORDIC
• ALTIMMUNE
• DYNAVAX TECHNOLOGIES
• SIGA TECHNOLOGIES
• ELUSYS THERAPEUTICS, INC.
• FABENTECH BIOTECH
• CLEVELAND BIOLABS, INC.
• OLOGY BIOSERVICES, INC.
• NOVAVAX, INC.

第11章 附录

Global Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

Market Overview

During the forecast period, the Biodefense Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.01%.

In preparation for potential bioterrorism attacks, governments are allocating substantial resources to vaccine research and development. Pharmaceutical companies that operate in the biodefense market have been presented with substantial opportunities to expand as a result of government initiatives to prepare for any form of bioterrorism. Additionally, governments worldwide are implementing initiatives to improve their biodefense capabilities. The biodefense market is experiencing growth because of increased funding for research and development, preparedness planning, infrastructure development, and the procurement of vaccines and medications.

Market segment insights

Anthrax, smallpox, botulism, influenza, radiation/nuclear, and other diseases comprise the Biodefense Market segmentation organized by disease type.

The segmentation of the Biodefense Market is based on the treatment, which includes vaccination and medication.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Biodefense market held the greatest market share. This is a result of the increasing prevalence of infectious diseases in the region, including HIV, viral hepatitis, and influenza. For example, the Centers for Disease Control and Prevention (CDC) estimated that approximately 9 million individuals in the United States were diagnosed with the influenza virus in 2021. This trend is anticipated to continue as antimicrobial resistance continues to increase. Furthermore, the market is anticipated to be driven by the increasing demand for affordable diagnostic tests, vaccines, and therapeutics to combat these infectious diseases.

The second-largest market share in the Europe Biodefense market is attributed to the increasing prevalence of chronic diseases and the increase in research and development activities for biodefense solutions throughout the region. Additionally, the German biodefense market was identified as having the greatest market share, while the Rest of Europe biodefense market is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific Biodefense market will experience substantial growth from 2023 to 2032. The primary factor fueling the market's growth is the rise in the prevalence of the patient population throughout the region. The region's consumers are facing a significant health risk due to the widespread epidemics of infectious diseases, including influenza and Covid-19, as well as the rise in the number of reported infections of communicable diseases. Moreover, the Japan Biodefense market is anticipated to have the highest market share, while the Rest of Asia-Pacific Biodefense market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. An increase in the prevalence of infectious diseases, including influenza and Covid-19, is expected to drive growth in the biodefense market in the regions.

Major Players

Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are among the key companies in the Biodefense Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
  • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA MINING
• 3.3 SECONDARY RESEARCH
• 3.4 PRIMARY RESEARCH
  • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING GOVERNMENT INITIATIVES AND FUNDING
  • 4.2.2 RISE IN DEMAND FOR VACCINES
• 4.3 RESTRAINTS
  • 4.3.1 LOW MARKET PENETRATION IN DEVELOPING AND UNDERDEVELOPED COUNTRIES
• 4.4 OPPORTUNITIES
  • 4.4.1 TECHNOLOGICAL ADVANCEMENT

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL BIODEFENSE MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTION
  • 5.3.3 IMPACT ON REGIONS
  • 5.3.4 IMPACT ON PRICING
• 5.4 AUTHORITIES BUDGET AND FINANCING PROGRAMS FOR BIODEFENSE BY REGION

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

• 6.1 OVERVIEW
• 6.2 ANTHRAX
• 6.3 SMALL POX
• 6.4 BOTULISM
• 6.5 INFLUENZA
• 6.6 RADIATION/NUCLEAR
• 6.7 OTHERS

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

• 7.1 OVERVIEW
• 7.2 VACCINATION
• 7.3 MEDICATION

8 GLOBAL BIODEFENSE MARKET, BY REGION

• 8.1 GLOBAL OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 UK
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 JAPAN
  • 8.4.2 INDIA
  • 8.4.3 SOUTH KOREA
  • 8.4.4 AUSTRALIA
  • 8.4.5 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 AFRICA
  • 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN GLOBAL BIODEFENSE MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BIODEFENSE MARKET
• 9.5 KEY DEVELOPMENT ANALYSIS
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • 9.6.2 PARTNERSHIP/COLLABORATION/AGREEMENT
  • 9.6.3 ACQUISITION/EXPANSION/INVESTMENT
• 9.7 MAJOR PLAYERS FINANCIAL
  • 9.7.1 SALES,
  • 9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

10 COMPANY PROFILE

• 10.1 EMERGENT
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 BAVARIAN NORDIC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 ALTIMMUNE
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 DYNAVAX TECHNOLOGIES
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 SIGA TECHNOLOGIES
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 ELUSYS THERAPEUTICS, INC.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 KEY STRATEGIES
• 10.7 FABENTECH BIOTECH
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 CLEVELAND BIOLABS, INC.
  • 10.8.1 COMPANY OVERVIEWS
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 OLOGY BIOSERVICES, INC.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 NOVAVAX, INC.
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 BIODEFENSE BUDGET, BY REGION, 2023 (USD MILLION)
• TABLE 3 GLOBAL BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• TABLE 4 GLOBAL BIODEFENSE MARKET, BY REGION, 2019-2030 (USD MILLION)
• TABLE 5 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 6 NORTH AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 7 NORTH AMERICA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 8 NORTH AMERICA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE 2019-2030 (USD MILLION)
• TABLE 9 US: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 10 US: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 11 US: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE,2019-2030 (USD MILLION)
• TABLE 12 CANADA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 13 CANADA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 14 CANADA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 15 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 16 EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 17 EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 18 EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 19 GERMANY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 20 GERMANY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 21 GERMANY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 22 UK: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 23 UK: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 24 UK: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 25 FRANCE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 26 FRANCE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 27 FRANCE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 28 ITALY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 29 ITALY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 30 ITALY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 31 SPAIN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 32 SPAIN: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 33 SPAIN: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 34 REST OF EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 35 REST OF EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 36 REST OF EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 37 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 38 ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 39 ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 40 ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 41 JAPAN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 42 JAPAN: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 43 JAPAN: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 44 INDIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 45 INDIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 46 INDIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 47 SOUTH KOREA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 48 SOUTH KOREA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 49 SOUTH KOREA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 50 AUSTRALIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 51 AUSTRALIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 52 AUSTRALIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 53 REST OF ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 54 REST OF ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 55 REST OF ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 56 REST OF THE WORLD: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 57 REST OF THE WORLD: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 58 REST OF THE WORLD: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 59 REST OF THE WORLD: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 60 MIDDLE EAST: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 61 MIDDLE EAST: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 62 MIDDLE EAST: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 63 AFRICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 64 AFRICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 65 AFRICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 66 LATIN AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 67 LATIN AMERICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 68 LATIN AMERICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 69 MAJOR PLAYERS IN GLOBAL BIODEFENSE MARKET
• TABLE 1 MOST ACTIVE PLAYER IN GLOBAL BIODEFENSE MARKET
• TABLE 2 PRODUCT LAUNCH/ PRODUCT APPROVAL
• TABLE 3 PARTNERSHIP/ COLLABORATION /AGREEMENT
• TABLE 4 ACQUISITION/EXPANSION/INVESTMENT
• TABLE 5 EMERGENT: PRODUCTS OFFERED
• TABLE 6 EMERGENT: KEY DEVELOPMENTS
• TABLE 7 BAVARIAN NORDIC: PRODUCTS OFFERED
• TABLE 8 BAVARIAN NORDIC: KEY DEVELOPMENTS
• TABLE 9 ALTIMMUNE: PRODUCTS OFFERED
• TABLE 10 DYNAVAX TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 11 DYNAVAX TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 12 SIGA TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 13 SIGA TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 14 ELUSYS THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 15 ELUSYS THERAPEUTICS, INC.: KEY DEVELOPMENTS
• TABLE 16 FABENTECH BIOTECH: PRODUCTS OFFERED
• TABLE 17 FABENTECH BIOTECH: KEY DEVELOPMENTS
• TABLE 18 CLEVELAND BIOLABS, INC.: PRODUCTS OFFERED
• TABLE 19 OLOGY BIOSERVICES, INC.: PRODUCTS OFFERED
• TABLE 20 OLOGY BIOSERVICES, INC.: KEY DEVELOPMENTS
• TABLE 21 NOVAVAX, INC.: PRODUCTS OFFERED
• TABLE 22 NOVAVAX, INC.: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 GLOBAL BIODEFENSE MARKET STRUCTURE
• FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 3 MARKET DYNAMICS: GLOBAL BIODEFENSE MARKET
• FIGURE 4 DRIVER IMPACT ANALYSIS
• FIGURE 5 RESTRAINT IMPACT ANALYSIS
• FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL BIODEFENSE MARKET
• FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIODEFENSE MARKET
• FIGURE 8 GLOBAL BIODEFENSE MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 9 GLOBAL BIODEFENSE MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 10 GLOBAL BIODEFENSE MARKET SHARE, BY REGION, 2023 (% SHARE)
• FIGURE 11 GLOBAL BIODEFENSE MARKET, BY REGION, 2023 & 2030 (USD MILLION)
• FIGURE 12 NORTH AMERICA MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
• FIGURE 13 NORTH AMERICA: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
• FIGURE 14 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
• FIGURE 15 EUROPE MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
• FIGURE 16 EUROPE: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
• FIGURE 17 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
• FIGURE 18 ASIA-PACIFIC MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• FIGURE 19 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019 & 2030 (USD MILLION)
• FIGURE 20 ASIA-PACIFIC: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
• FIGURE 21 REST OF THE WORLD MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• FIGURE 22 REST OT THE WORLD: BIODEFENSE MARKET, BY REGION, 2019 & 2030 (USD MILLION)
• FIGURE 23 REST OF THE WORLD: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
• FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 25 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL BIODEFENSE MARKET
• FIGURE 26 GLOBAL BIODEFENSE MARKET: COMPETITIVE LANDSCAPE
• FIGURE 27 MAJOR PLAYERS SALES,
• FIGURE 28 MAJOR PLAYERS R&D EXPENDITURE,
• FIGURE 29 EMERGENT: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 30 EMERGENT: SWOT ANALYSIS
• FIGURE 31 BAVARIAN NORDIC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 BAVARIAN NORDIC: SWOT ANALYSIS
• FIGURE 33 ALTIMMUNE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 DYNAVAX TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 SIGA TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 36 SIGA TECHNOLOGIES: SWOT ANALYSIS
• FIGURE 37 FABENTECH BIOTECH: SWOT ANALYSIS
• FIGURE 38 CLEVELAND BIOLABS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 39 NOVAVAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 40 NOVAVAX, INC.: SWOT ANALYSIS